Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?
Here is how Agilon Health (AGL) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Illumina (ILMN) have performed compared to their sector so far this year.
Has Agilon Health (AGL) Outpaced Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Agilon Health Q2 Earnings Call Highlights
Agilon Health NYSE: AGL reported second-quarter results that exceeded its guidance for medical margin and adjusted EBITDA, citing stronger risk-adjustment revenue, favorable medical-cost development and progress in its clinical and quality initiatives. The company also raised its full-year 2026 outlook.
Agilon Health (AGL) Tops Q2 Earnings and Revenue Estimates
Agilon Health (AGL) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $6.25 per share a year ago.
Agilon (AGL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Agilon Health (AGL) Is Up 0.79% in One Week: What You Should Know
Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Fast-paced Mover Agilon (AGL) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agilon (AGL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
agilon health: Q1 Inflection And A New CEO Set Up A Multi-Year Rerating
agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational.
Is the Options Market Predicting a Spike in agilon health Stock?
Investors need to pay close attention to AGL stock based on the movements in the options market lately.
Are You Looking for a Top Momentum Pick? Why Agilon Health (AGL) is a Great Choice
Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Agilon Health (AGL) This Year?
Here is how Agilon Health (AGL) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.
